We are live on
!
Find out more
BCPEM
Bain Capital Public Equity Management Portfolio holdings
AUM
$1.05B
1-Year Est. Return
25.71%
This Fund
S&P 500
This Quarter
Est. Return
+14.94%
1 Year Est. Return
+25.71%
3 Year Est. Return
+127.65%
5 Year Est. Return
+213.44%
10 Year Est. Return
–
AUM
$3.99B
AUM Growth
-$285M
(-6.7%)
Cap. Flow
-$784M
Cap. Flow
% of AUM
-19.68%
Top 10 Holdings %
Top 10 Hldgs %
44.74%
Holding
61
New
18
Increased
5
Reduced
19
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BRCM
BROADCOM CORP CL-A
BRCM
|
+$161M |
| 2 |
SWI
SOLARWINDS INC COM STK (DE)
SWI
|
+$102M |
| 3 |
MHFI
MCGRAW-HILL FINANCIAL INC COM
MHFI
|
+$73.5M |
| 4 |
Herc Holdings
HRI
|
+$55.8M |
| 5 |
AMC Global Media
AMCX
|
+$50.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ESRX
Express Scripts Holding Company
ESRX
|
+$149M |
| 2 |
Gilead Sciences
GILD
|
+$127M |
| 3 |
PPG Industries
PPG
|
+$114M |
| 4 |
NWSA
NEWS CORPORATION CL-A
NWSA
|
+$88.7M |
| 5 |
EMC
EMC CORPORATION
EMC
|
+$80.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.37% |
| 2 | Consumer Staples | 15.36% |
| 3 | Consumer Discretionary | 13.1% |
| 4 | Healthcare | 10.75% |
| 5 | Industrials | 10.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
IQVIA
IQV
$39.3B
| $66.1M | 1.66% |
1,472,940
| – | – |
|
|
IDIX
27
DELISTED
IDENIX PHARMACEUTICALS INC
IDIX
| $65.7M | 1.65% |
12,664,950
| – | – |
|
|
PARA
28
DELISTED
Paramount Global Class B
PARA
| $59.9M | 1.5% |
1,086,611
-546,000
| -33% | -$29M |
|
|
PTLA
29
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $58.4M | 1.47% |
2,185,013
| – | – |
|
|
30
AMC Global Media
AMCX
$489M
| $52.2M | 1.31% |
+762,400
| New | +$50.5M |
|
31
PTC Therapeutics
PTCT
$6.12B
| $50.1M | 1.26% |
+2,333,333
| New | +$40.6M |
|
|
MDVN
32
DELISTED
MEDIVATION, INC.
MDVN
| $49.5M | 1.24% |
1,651,374
-2,602,776
| -61% | -$74.3M |
|
|
HMIN
33
DELISTED
HOMEINNS HOTEL GROUP SPONSORED ADR
HMIN
| $40.6M | 1.02% |
1,221,604
| – | – |
|
|
RKUS
34
DELISTED
RUCKUS WIRELESS INC COM STK (DE)
RKUS
| $39.2M | 0.98% |
2,327,700
-935,300
| -29% | -$13.6M |
|
35
Autodesk
ADSK
$52.6B
| $34.4M | 0.86% |
+836,435
| New | +$30.9M |
|
36
Illumina
ILMN
$28.4B
| $29.6M | 0.74% |
376,343
-862,397
| -70% | -$66M |
|
37
Sarepta Therapeutics
SRPT
$1.77B
| $23.6M | 0.59% |
+500,000
| New | +$19.3M |
|
38
Alnylam Pharmaceuticals
ALNY
$29.3B
| $22.4M | 0.56% |
+350,100
| New | +$17.5M |
|
39
Puma Biotechnology
PBYI
$454M
| $17.9M | 0.45% |
332,791
-411,612
| -55% | -$22.2M |
|
|
GEVA
40
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
| $16.9M | 0.42% |
+266,141
| New | +$13.1M |
|
41
Telefônica Brasil
VIV
$19.2B
| $16.2M | 0.41% |
+721,352
| New | +$15.5M |
|
42
Agios Pharmaceuticals
AGIO
$1.93B
| $14.6M | 0.37% |
+521,800
| New | +$14.4M |
|
43
ICICI Bank
IBN
$108B
| $13M | 0.33% |
+2,338,600
| New | +$13.7M |
|
|
ALU
44
DELISTED
Alcatel-Lucent
ALU
| $9.07M | 0.23% |
2,673,288
-11,671,952
| -81% | -$29.8M |
|
|
RGLS
45
DELISTED
Regulus Therapeutics
RGLS
| $8.49M | 0.21% |
+7,500
| New | +$8.85M |
|
|
BIND
46
DELISTED
BIND THERAPEUTICS INC
BIND
| $6.35M | 0.16% |
+450,000
| New | +$6.48M |
|
|
BCOV
47
DELISTED
Brightcove, Inc.
BCOV
| $5.85M | 0.15% |
520,006
| – | – |
|
48
Fortress Biotech
FBIO
$88.7M
| $5.43M | 0.14% |
+51,667
| New | +$6.33M |
|
49
Cognizant
CTSH
$26B
| $5.06M | 0.13% |
+123,134
| New | +$4.57M |
|
|
CYNI
50
DELISTED
CYAN INC COM
CYNI
| $3.52M | 0.09% |
350,000
| – | – |
|
Similar funds
WF
DCM
AB
MFBTD
IAS
SA
TL
ACM
Bain Capital Public Equity Management's Q3 2013 Portfolio in Review
As of Q3 2013, Bain Capital Public Equity Management held 61 positions worth $3.99B, down 6.7% from $4.27B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Bain Capital Public Equity Management withdrew a net $784M in Q3 2013, closing 9 positions and reducing 19 holdings. Its most notable exit was Express Scripts Holding Company, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 16% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
Against the trend, Bain Capital Public Equity Management opened a new position in BROADCOM CORP CL-A worth $149M.
- Bain Capital Public Equity Management's largest Q3 2013 buy was BROADCOM CORP CL-A: 5,716,500 shares worth $149M.
- Bain Capital Public Equity Management added most to Herc Holdings in Q3 2013, an estimated $55.8M increase.
- Bain Capital Public Equity Management's biggest Q3 2013 reduction was Gilead Sciences, cutting an estimated $127M.
- Bain Capital Public Equity Management fully exited Express Scripts Holding Company in Q3 2013, selling an estimated $149M.
- Bain Capital Public Equity Management's ten largest holdings make up 45% of its $3.99B portfolio in Q3 2013.
- Bain Capital Public Equity Management opened 18 new positions and closed 9 in Q3 2013.
- Bain Capital Public Equity Management's portfolio value fell 6.7% quarter-over-quarter to $3.99B.
Based on Bain Capital Public Equity Management's 13F filing for Q3 2013, filed 12 Nov 2013.